AQST - Aquestive surges 31% after topline data for oral epinephrine candidate

Aquestive Therapeutics (NASDAQ:AQST) added ~31% in the post-market Wednesday after the commercial-stage pharma company announced topline results from the first three arms of Part 3 of the randomized, open-label study for AQST-109 epinephrine oral film. The three-part crossover EPIPHAST study involving healthy adult subjects is designed to compare epinephrine delivered as AQST-109 in an oral film against intramuscular injection of epinephrine. The trial indicated that the median time to maximum concentration of AQST-109 was 12 minutes compared to 50 minutes for the epinephrine 0.3mg IM route in the Part 2 of the study. The median time to reach 100 pg/mL that indicates the level to generate hemodynamic effects, was 8 minutes for AQST-109 while Part 2 of the study showed 10 minutes for the 0.3mg IM injection. AQST-109 continued to remain safe and well tolerated during the trial, the company said. In 3Q 2022, Aquestive (AQST) plans to trial AQST-109 and 0.3

For further details see:

Aquestive surges 31% after topline data for oral epinephrine candidate